Zelira Therapeutics Ltd. announced that its proprietary cannabinoid medicine ZenivolTM can now be prescribed to patients in Australia through the Therapeutic Goods Administration's (TGA) Special Access Scheme and via Authorised Prescribers. ZenivolTM is available for immediate supply via Zelira's national distribution partner Health House. Zelira recently successfully completed a world-first; a clinical trial powered to show statistical significance through a randomised, double-blind, cross-over designed Phase 2A clinical study in patients suffering from chronic insomnia treated with ZenivolTM. The results confirmed that ZenivolTM is a safe and effective therapy for chronic insomnia. ZenivolTM treatment significantly improved key insomnia symptoms, as measured using the Insomnia Severity Index (ISI) - a current standard for measuring effectiveness of insomnia treatment, and was not associated with any serious adverse events. This trial was conducted at the world-class University of Western Australia (UWA) Centre for Sleep Science. Analysis of secondary endpoints showed patients treated with ZenivolTM slept longer, went to sleep faster and went back to sleep sooner after waking. Patients also reported statistically significant improvements in quality of life measures including feeling rested after sleep, feeling less stressed, less fatigued and improved overall functioning.